The present randomized controlled study investigated the effect of sitagliptin treatment, the first available DPP-4 inhibitor in Japan, on serum adiponectin level in Japanese T2DM subjects, compared to conventional treatment (sulfonylurea [SU] and/or biguanide drugs). The gene discussed is ADIPOQ; the disease is type 2 diabetes mellitus.